NEWS
GADx co-founder Mark Davis steps down after 20 years
Global Access Diagnostics (GADx) has announced that co-founder Mark Davis is stepping down as CEO after 20 years, having founded the company as Mologic in June 2003, alongside his father and industry leader Professor Paul Davis.
Paul Davis was part of the original team that pioneered lateral flow technology and its deployment in the ClearBlue home pregnancy
test, and together they guided the company to its position today as a leading innovator and developer of diagnostic products. The move represents a major milestone
in the journey of Mologic to transform from a privately held company to GADx, a social enterprise that reinvests its profits entirely in pursuit of global health programmes. Over the past two decades, the organisation embraced creative solutions and blue- sky thinking to partner with hundreds of
clients across the globe, to train the next generation of diagnostic innovators in the UK, US, and Senegal, and to develop innovative approaches for unmet diagnostic needs.
For several months, the members and Mark Davis have been preparing for this transition, acknowledging the unique skillset and strategy required to grow commercial activities
alongside expertise in developing diagnostics for neglected diseases and unmet needs. GADx’s parent company Global Access Health has contracted with the Clinton Health Access Initiative (CHAI) to provide management services to support the organisation through the CEO transition. Dr Randy Allen, a Director in the Global Markets Team at CHAI will be seconded to the organisation as acting General Manager.
Introducing Revvity – a scientific solutions company powering innovation
Revvity has been officially launched as a science-based solutions company that leverages innovation across life sciences and diagnostics to help improve lives everywhere. The Revvity name is the new brand for Horizon Discovery, the Cambridge life science company acquired by PerkinElmer in November 2020. Born from two words, ‘revolutionise’
(rev) and ‘vita’ (vit) meaning ‘life’ in Latin, Revvity delivers end-to-end expertise and solutions from research discovery to development, and diagnosis to cure. “The unveiling of Revvity is the capstone of a nearly year-long journey that has transformed who we are and reinforces why our work matters,” said Prahlad Singh, President and CEO of Revvity. Revvity provides reagents, consumables, assays, instruments and software to customers in markets ranging from pharma and biotech, diagnostic laboratories, academia and government
agencies. Industry leading franchises, BioLegend, EUROIMMUN, Tulip Diagnostics and ViaCord retain their own names as unique product lines. The company’s comprehensive scientific software platform, previously known as PerkinElmer Informatics, will become Revvity Signals Software. Revvity Omics replaces PerkinElmer Genomics as the company’s genomics services business. Cisbio, Horizon Discovery, Nexcelom Bioscience, Omni International, Oxford Immunotec, SIRION Biotech and SonoVol will now identify as Revvity, while maintaining their specific product names.
Available from our
stock range - enquire now!
IVD solutions through partnership
MAST DISCS®
ID
Nitrocefi n Discs
Rapid detection of ß-lactamase enzymes
Contact us today for more information
www.mast-group.com
WWW.PATHOLOGYINPRACTICE.COM JUNE 2023 11
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
